Education
About Us
Working with TipRanks
Follow Us
Capstone Therapeutics Corp (CAPS)
NASDAQ:CAPS
Total Valuation
Capstone Therapeutics has a market cap or net worth of $7.64M. The enterprise value is $29.73M.
Market Cap$7.64M
Enterprise Value$29.73M
Share Statistics
Capstone Therapeutics has 7,906,205 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding7,906,205
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Capstone Therapeutics’s return on equity (ROE) is 0.84 and return on invested capital (ROIC) is -1.25%.
Return on Equity (ROE)0.84
Return on Assets (ROA)-0.05
Return on Invested Capital (ROIC)-1.25%
Return on Capital Employed (ROCE)-0.02
Revenue Per Employee1.25M
Profits Per Employee-71.19K
Employee Count36
Asset Turnover0.95
Inventory Turnover3.73
Valuation Ratios
The current PE Ratio of Capstone Therapeutics is ―. Capstone Therapeutics’s PEG ratio is 0.03.
PE Ratio―
PS Ratio0.00787
PB Ratio-0.12
Price to Fair Value-0.12
Price to FCF0.10
Price to Operating Cash Flow-3.91
PEG Ratio0.03
Income Statement
In the last 12 months, Capstone Therapeutics had revenue of 44.88M and earned -2.56M in profits. Earnings per share was -34.86.
Revenue44.88M
Gross Profit9.57M
Operating Income-638.00K
Pretax Income-3.00M
Net Income-2.56M
EBITDA-121.00K
Earnings Per Share (EPS)-34.86
Cash Flow
In the last 12 months, operating cash flow was -1.15M and capital expenditures -21.00K, giving a free cash flow of -1.17M billion.
Operating Cash Flow-1.15M
Free Cash Flow-1.17M
Free Cash Flow per Share-0.15
Dividends & Yields
Capstone Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.97
52-Week Price Change-69.16%
50-Day Moving Average1.04
200-Day Moving Average1.67
Relative Strength Index (RSI)51.30
Average Volume (3m)1.37M
Important Dates
Capstone Therapeutics upcoming earnings date is Apr 7, 2026, TBA (Confirmed).
Last Earnings DateAug 19, 2025
Next Earnings DateApr 7, 2026
Ex-Dividend Date―
Financial Position
Capstone Therapeutics as a current ratio of 1.02, with Debt / Equity ratio of 59.01%
Current Ratio1.02
Quick Ratio0.27
Debt to Market Cap40.89
Net Debt to EBITDA-137.20
Interest Coverage Ratio-0.43
Taxes
In the past 12 months, Capstone Therapeutics has paid -442.00K in taxes.
Income Tax-442.00K
Effective Tax Rate0.15
Enterprise Valuation
Capstone Therapeutics EV to EBITDA ratio is -140.12, with an EV/FCF ratio of 4.58.
EV to Sales0.38
EV to EBITDA-140.12
EV to Free Cash Flow4.58
EV to Operating Cash Flow4.44
Balance Sheet
Capstone Therapeutics has $730.00K in cash and marketable securities with $23.25M in debt, giving a net cash position of -$22.52M billion.
Cash & Marketable Securities$730.00K
Total Debt$23.25M
Net Cash-$22.52M
Net Cash Per Share-$2.85
Tangible Book Value Per Share-$167.45
Margins
Gross margin is 21.87%, with operating margin of -1.42%, and net profit margin of -5.71%.
Gross Margin21.87%
Operating Margin-1.42%
Pretax Margin-6.70%
Net Profit Margin-5.71%
EBITDA Margin-0.27%
EBIT Margin-1.42%
Analyst Forecast
The average price target for Capstone Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target―
Price Target Upside―
Analyst ConsensusHold
Analyst Count0
Revenue Growth Forecast1.52%
EPS Growth Forecast77.22%